Anticancer Drugs

Bevacizumab, the first FDA-approved anti-angiogenic drug, revolutionized cancer treatment by inhibiting vascular endothelial growth factor (VEGF) to suppress tumour blood vessel formation.

Tyrosine kinase inhibitors (TKIs) are cancer therapies that were part of a revolutionary new ‘targeted’ approach to cancer treatment that was introduced into clinical practice around the start of the 2000s. They are small molecules rationally designed to interfere with signals that play a role in helping cancer cells survive and grow.

Vinorelbine (also named Navelbine) is an anti-tumor semi-synthetic vinca-alkaloid compound discovered in France and mainly used in breast cancer and non-small cell lung cancer. The original vinca-alkaloids were derived from the dried leaves of the Madagascan periwinkle (vinca rosea).

Brain tumours are among the cancers with the worst outlook and are hard to treat owing to factors such as inoperable locations in the brain and the difficulty of developing drugs that can cross the blood-brain barrier.

Adriamycin is an anti-tumor antibiotic discovered in Italy, which has been and is still being used in a wide variety of tumors. The laboratory and the initial clinical studies leading to the demonstration of its usefulness were carried out in Italy.

Chemotherapies are still essential to treat many cancer patients, and platinum-based drugs are among the most widely deployed. Successive generations of platinum agents are a European success story.

Chemotherapies are still essential to treat many cancer patients, and platinum-based drugs are among the most widely deployed. Successive generations of platinum agents are a European success story.

Chemotherapies are still essential to treat many cancer patients, and platinum-based drugs are among the most widely deployed. Successive generations of platinum agents are a European success story.